ATE247462T1 - Verwendung von metformin gegen die gewichtszunahme, die mit valproat und andere psychotropische arzneimittel verbunden ist - Google Patents

Verwendung von metformin gegen die gewichtszunahme, die mit valproat und andere psychotropische arzneimittel verbunden ist

Info

Publication number
ATE247462T1
ATE247462T1 AT99952021T AT99952021T ATE247462T1 AT E247462 T1 ATE247462 T1 AT E247462T1 AT 99952021 T AT99952021 T AT 99952021T AT 99952021 T AT99952021 T AT 99952021T AT E247462 T1 ATE247462 T1 AT E247462T1
Authority
AT
Austria
Prior art keywords
valproate
metformin
weight gain
gain associated
psychotropic drugs
Prior art date
Application number
AT99952021T
Other languages
English (en)
Inventor
Elizabeth Marie Cottingham
Original Assignee
Cottingham Elizabeth M
Morrison John A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cottingham Elizabeth M, Morrison John A filed Critical Cottingham Elizabeth M
Application granted granted Critical
Publication of ATE247462T1 publication Critical patent/ATE247462T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT99952021T 1998-10-15 1999-10-15 Verwendung von metformin gegen die gewichtszunahme, die mit valproat und andere psychotropische arzneimittel verbunden ist ATE247462T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10439498P 1998-10-15 1998-10-15
US09/416,330 US6194466B1 (en) 1998-10-15 1999-10-12 Use of metformin to counteract weight gain associated with valproate and other psychotropic medications
PCT/US1999/024262 WO2000021522A1 (en) 1998-10-15 1999-10-15 Use of metformin to counteract weight gain associated with valproate and other psychotropic medications

Publications (1)

Publication Number Publication Date
ATE247462T1 true ATE247462T1 (de) 2003-09-15

Family

ID=26801492

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99952021T ATE247462T1 (de) 1998-10-15 1999-10-15 Verwendung von metformin gegen die gewichtszunahme, die mit valproat und andere psychotropische arzneimittel verbunden ist

Country Status (6)

Country Link
US (1) US6194466B1 (de)
EP (1) EP1121110B1 (de)
AT (1) ATE247462T1 (de)
AU (1) AU6432899A (de)
DE (1) DE69910600T2 (de)
WO (1) WO2000021522A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4167742B2 (ja) * 1998-01-23 2008-10-22 中央発條株式会社 押し引きコントロールケーブル
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
US20060246131A1 (en) * 2005-04-28 2006-11-02 Cottlingham Elizabeth M Use of metformin to counteract weight gain associated with psychotropic medications
WO2008090534A1 (en) * 2007-01-26 2008-07-31 Berand Limited Methods and compositions for inhibition of excessive weight gain, reduction of inappropriate eating behaviours and inhibition of binge eating for the treatment of obesity
EP3328494A4 (de) 2015-08-01 2019-04-03 Stephen J. Petti Zusammensetzungen und verfahren zur kombination pharmakologischer behandlungen zur induktion einer verlängerten, milden abnahme der körperkerntemperatur
EP3837352A1 (de) 2018-08-17 2021-06-23 Frequency Therapeutics, Inc. Zusammensetzungen und verfahren zur erzeugung von haarzellen durch hochregulieren von jag-1
US11617745B2 (en) * 2018-08-17 2023-04-04 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating FOXO

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4432757A1 (de) * 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung

Also Published As

Publication number Publication date
EP1121110B1 (de) 2003-08-20
AU6432899A (en) 2000-05-01
DE69910600T2 (de) 2004-06-24
DE69910600D1 (de) 2003-09-25
EP1121110A1 (de) 2001-08-08
US6194466B1 (en) 2001-02-27
WO2000021522A1 (en) 2000-04-20

Similar Documents

Publication Publication Date Title
GEP20063799B (en) Tropane derivatives useful in therapy
MY119403A (en) Novel compounds with analgesic effect.
TR199801180T2 (xx) Aneljestik etkiye sahip yeni bile�ikler.
DK0740650T3 (da) Codrugs som metode til styret transport af lægemiddel
TR200102962T2 (tr) Yeni tedavi metodu.
MY132705A (en) Novel compounds with analgesic effect
NZ540385A (en) Use of 1-oxo-2-(2, 6-dioxopiperidin-3-yl)-4-methylisoindoline in the manufacture of a medicamnent for treatment of brain cancer
AU2506388A (en) Azelastine-containing medicaments for application in the nose and/or at the eye
NO307495B1 (no) Anvendelse av riluzol ved fremstilling av medikamenter for behandling av Parkinsons sykdom og Parkinsonske syndromer
DE69531098D1 (de) Piperidine und pyrrolidine
BR0013065A (pt) Método e composto para tratar de uma doença associada com recrutamento e/ ou ativação aberrante de leucócitos
DE60143911D1 (de) Antitumorzusammensetzungen welche ecteinascidin 743 enthalten
BG106171A (en) Compositions and uses of et743 for treating cancer
ATE99172T1 (de) Verwendung von acetyl-l-carnitin zur behandlung von katarakt, sowie pharmazeutische zusammensetzungen fuer eine derartige behandlung.
HK1077215A1 (en) A pharmaceutical composition for treatment of acute myocardial infarction
DE69200711T2 (de) Pharmazeutische Zusammensetzungen enthaltend Fluticasonpropionat und Oxikonazol oder dessen Salz zur lokalen Anwendung.
ATE247462T1 (de) Verwendung von metformin gegen die gewichtszunahme, die mit valproat und andere psychotropische arzneimittel verbunden ist
NO943288L (no) Anvendelse av pentoksyfyllin ved fremstilling av farmasöytiske preparater til behandling av granulomatöse og fibroserende lungesykdommer
DE69111974T2 (de) Verwendung von Lithium zur Behandlung oder Prophylaxe von Molluscum contagiusum.
BR0009380A (pt) Tratamento de câncer melhorado comtemozolomida
JPS6483020A (en) Medicinal composition for preventing or treating aids
AU3401093A (en) Therapeutic agent for threatened abortion
YU25202A (sh) Supstituisani piroli kao antiproliferativna sredstva za lečenje kancera
ES2053683T3 (es) Forma de medicamento de aplicacion oral para el tratamiento de la hipertension una vez al dia con hidrocloruro de diltiazem.
SE9101341D0 (sv) New medicinal use

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties